Antimicrobial Resistance Training Program in the Texas Medical Center (AMR-TPT)
Project Number1T32AI179595-01
Contact PI/Project LeaderARIAS, CESAR AUGUSTO
Awardee OrganizationMETHODIST HOSPITAL RESEARCH INSTITUTE
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT
The rise of antibiotic-resistant microorganisms globally has become a critical public health priority due to the
devastating consequences that it may have to the world health and economy. Antibiotic resistance (AMR)
threatens the progress of medicine in all areas, and as such, the issue has reached the highest level of
government, including the Office of the US President and the United Nations. AMR is a top public health
priority for both CDC and WHO and has been designated as the “silent” pandemic. Houston is the home to the
largest cluster of healthcare institutions in the world, the Texas Medical Center (TMC), with more than 9,200
hospital beds and 10 million patient visits per year. The Houston area’s strong history of outstanding infectious
diseases research and training includes a focus on AMR and antibiotic stewardship. The combined efforts of
the recently formed Houston Methodist Center of Excellence for Infectious Diseases and the existing Gulf
Coast Consortium (GCC) for Antimicrobial Resistance have resulted in an active, multidisciplinary and
comprehensive research and educational program amalgamating the endeavors of AMR researchers and
creating the resources, personnel, funding and fertile ground to develop an ambitious, innovative, unparalleled
AMR training program. We propose to establish the AMR Training Program in the Texas Medical Center
(AMR-TPT) that trains postdoctoral scholars, clinical residents/fellows and PharmD fellows from eight
institutions in the TMC (Houston Methodist Research Institute, University of Texas Health Science Center at
Houston, MD Anderson Cancer Center, Baylor College of Medicine, University of Texas Medical Branch, Rice
University, University of Houston, and Institute of Biosciences and Technology of Texas A&M University) on
advanced aspects of AMR research. We will take advantage of the strong administrative expertise of the GCC
on successful T32 programs in other areas and the educational activities already in place, combined with the
expertise of world-class AMR researchers. AMR-TPT seeks to leverage and create resources to train the next
generation of scientists and clinician-scientists (MDs, PhDs and PharmDs) focused on tackling the pressing
AMR public health crisis. The highly collaborative environment provides the perfect opportunity for trainees to
acquire the skills, expertise and intellectual abilities to foster innovative research that has a strong translational
component and could be developed to directly influence patient care. Along with a highly interactive AMR
Foundations course and myriad career/professional development opportunities, the proposed training grant
includes expertise in and a focus on i) molecular basis of resistance, ii) bacterial genomics and bioinformatics,
iii) diagnostics, iv) pharmacological aspects of resistance, v) microbiome science, vi) clinical epidemiology and
biostatistics of AMR and vii) antibiotic stewardship. We believe we are poised to continue developing a unique,
innovative and comprehensive training program that truly provides trainees with exceptional tools and abilities
and creates a strong cohort of new world-class AMR leaders and researchers.
Public Health Relevance Statement
PROJECT NARRATIVE
Antimicrobial resistance (AMR) is one of the most critical public-health threats of the 21st century associated
with an estimated 4.95 million deaths in 2019. Our postdoctoral training program will prepare the next
generation of clinicians and scientists on the complex and multidisciplinary aspects of AMR. These trainees will
be poised to become future leaders in the field and tackle the dire impact that AMR has on human health.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
185641052
UEI
XJUCJAYJWYV1
Project Start Date
01-July-2024
Project End Date
30-June-2029
Budget Start Date
01-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$342,204
Direct Costs
$317,744
Indirect Costs
$24,460
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$342,204
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1T32AI179595-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1T32AI179595-01
Patents
No Patents information available for 1T32AI179595-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1T32AI179595-01
Clinical Studies
No Clinical Studies information available for 1T32AI179595-01
News and More
Related News Releases
No news release information available for 1T32AI179595-01
History
No Historical information available for 1T32AI179595-01
Similar Projects
No Similar Projects information available for 1T32AI179595-01